Payment overview · 2025
General Payments
$2,236.74
89 reported records · 28 companies
Healthcare provider profile · identity verified
Ric Scott Garrison, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PALMDALE, CA · NPI 1295814408
Verified facts
What the public records show
CMS Open Payments records show Ric Scott Garrison, M.D. received $2,236.74 in general payments during 2025 across 89 reported records.
ABBVIE INC. accounted for 10.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Viberzi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $227.60 | 10.2% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $204.64 | 9.2% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $158.36 | 7.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $155.17 | 6.9% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$134.93 | 6.0% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $129.56 | 5.8% | 4 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $117.92 | 5.3% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $116.56 | 5.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $99.20 | 4.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.82 | 3.6% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $78.06 | 3.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.70 | 3.5% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $77.03 | 3.4% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $68.96 | 3.1% | 4 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.05 | 2.8% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $59.09 | 2.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $55.14 | 2.5% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $53.75 | 2.4% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $48.14 | 2.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.48 | 2.0% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.77 | 1.5% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $30.80 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.45 | 1.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $20.57 | 0.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.34 | 0.9% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.69 | 0.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.16 | 0.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.80 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,236.74 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $177.73 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $132.49 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $129.56 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $123.23 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $123.23 | 4 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $117.92 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.66 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $99.20 | 4 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $97.55 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $78.06 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $77.03 | 4 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $73.65 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $68.96 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $64.61 | 4 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $62.05 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $59.39 | 4 | 2025 |
Source payment records
|
|||||
| INSIGNIA Normalized: insignia |
Device | Stryker Corporation | $59.09 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $55.14 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $53.90 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $53.75 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $53.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.24 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.24 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.48 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.48 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.48 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.77 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $30.80 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $30.39 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $30.39 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $30.24 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| ACCURIAN Normalized: accurian |
Device | Medtronic, Inc. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $20.57 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 125 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 244 | exact normalized | Medicare Part D |
| VIBERZI viberzi |
2025 | Viberzi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
244 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 422 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 352 | 132 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 289 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 246 | 92 |
| Ozempic | Semaglutide | 244 | 48 |
| Metformin Hcl | Metformin Hcl | 231 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 62 |
| Losartan Potassium | Losartan Potassium | 150 | 62 |
| Gabapentin | Gabapentin | 128 | 45 |
| Trazodone Hcl | Trazodone Hcl | 128 | 59 |
| Lisinopril | Lisinopril | 126 | 44 |
| Jardiance | Empagliflozin | 125 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 33 |
| Allopurinol | Allopurinol | 111 | 41 |
| Sertraline Hcl | Sertraline Hcl | 111 | 32 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 100 | 35 |
| Donepezil Hcl | Donepezil Hcl | 98 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 32 |
| Omeprazole | Omeprazole | 88 | 32 |
| Ezetimibe | Ezetimibe | 85 | 30 |
| Telmisartan | Telmisartan | 82 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 23 |
| Ibandronate Sodium | Ibandronate Sodium | 72 | 24 |
| Carvedilol | Carvedilol | 70 | 24 |
| Mounjaro | Tirzepatide | 67 | 19 |
| Chlorthalidone | Chlorthalidone | 63 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 24 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 60 | suppressed |
| Eliquis | Apixaban | 56 | 21 |
| Furosemide | Furosemide | 56 | 24 |
| Montelukast Sodium | Montelukast Sodium | 55 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 18 |
| Memantine Hcl | Memantine Hcl | 54 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 16 |
| Atenolol | Atenolol | 53 | 17 |
| Naproxen | Naproxen | 53 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 17 |
| Entresto | Sacubitril/Valsartan | 52 | 12 |
| Indapamide | Indapamide | 49 | 16 |
| Spironolactone | Spironolactone | 47 | 18 |
| Farxiga | Dapagliflozin Propanediol | 45 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 45 | 20 |
| Alendronate Sodium | Alendronate Sodium | 41 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 14 |
| Clonidine Hcl | Clonidine Hcl | 40 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 13 |
| Azithromycin | Azithromycin | 35 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 14 |
| Potassium Chloride | Potassium Chloride | 34 | 11 |
| Finasteride | Finasteride | 31 | 11 |
| Linzess | Linaclotide | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Famotidine | Famotidine | 30 | 12 |
| Fluconazole | Fluconazole | 30 | 22 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | 11 |
| Xarelto | Rivaroxaban | 28 | 11 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | 13 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Prednisone | Prednisone | 22 | 16 |
| Promethazine Hcl | Promethazine Hcl | 22 | 17 |
| Simvastatin | Simvastatin | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | 14 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Fluorouracil | Fluorouracil | 18 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Dotti | Estradiol | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Viberzi | Eluxadoline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,236.74 · 89 records | ABBVIE INC. | ABRYSVO, ACCRUFER, ACCURIAN, AIRSUPRA, AUSTEDO XR, BEYFORTUS, BREZTRI, CAPVAXIVE, COMIRNATY, DUPIXENT, Dexcom G6 Transmitter, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, GARDASIL 9, GEMTESA, INCEPTIV, INSIGNIA, JARDIANCE, JATENZO, Kerendia, Korlym, LINZESS, Leqembi, MINIMED 780G, MOUNJARO, NEXPLANON, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SUBLOCADE, Tlando, UZEDY, VERQUVO, VIBERZI, VRAYLAR, Veozah, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error